@FierceMedDev: Covidien yanks syringes over sterility risk. Report | Follow @FierceMedDev
@DamianFierce: Introducing B-a-MedFounder, a new crowdfunding platform for medical devices. ICYM yesterday's popular story | Follow @DamianFierce
@MarkHFierce: Medtronic reported a double-digit increase in net earnings during Q1. Release | Follow @MarkHFierce
@MichaelGFierce: ICYMI: Platinum-based radiotherapy method zaps cancer with nanomeds. More from FierceDrugDelivery | Follow @MichaelGFierce
> Attorneys have picked a jury for C.R. Bard's ($BCR) next vaginal mesh trial, following a $2 million verdict against the company last week. Story
> Insulin pumps proved better at improving glycemic control and reducing hypoglycemia than injections among children with Type 1 diabetes, according to a study. Article
> Respicardia has kicked off enrollment in its pivotal trial of the Remede device, designed to treat sleep apnea. News
> ERBA Diagnostics ($ERB) posted about $7 million in revenue last quarter, a 60% jump over the same period last year, and eked out a net income of $87,333, besting a $358,680 loss in the second quarter of 2012. Results
> Seven months since it kicked in, the medical device tax hasn't proved too much for industry to handle. More
> U.K. diagnostics outfit Biofortuna has raised about $2 million to expand its technology. Report
Biotech News
@FierceBiotech: ICYMI from FierceBiotechIT: Pfizer taps online marketplace for outsourcing research. Story | Follow @FierceBiotech
@JohnCFierce: I wonder if this will reignite some old rumors of a Novartis buyout for MorphoSys. I suspect so. Article | Follow @JohnCFierce
@RyanMFierce: Pfizer's social head touted some of the internal and external feats of the pharma giant. More | Follow @RyanMFierce
> Adimab adds Celgene to high-profile clientele for antibody drug discovery. News
> Regado has to slash IPO price to complete $42M raise. Report
> Eisai suit prods DEA for slow-motion drug classification roadblock. More
> Analyst urges Merck to overhaul its weak $8B R&D operation. Story
Pharma News
@FiercePharma: Popular this morning on our website: Eli Lilly's $15B battle for longer Alimta monopoly hits court today. Story | Follow @FiercePharma
@CarlyHFierce: The gang at FierceBiotech is looking for 2013's fiercest women in biotech. Submit nominations here. | Follow @CarlyHFierce
> Analyst to Merck: Get to work chopping costs, preferably $1B-plus. Story
> Shire said to enlist help fighting off unwanted takeover. More
Pharma Manufacturing News
@EricPFierce: WSJ: Eisai sues DEA to get it to move on epilepsy drug Fycompa, which FDA approved in October. FiercePharma story | Follow @EricPFierce
> FDA program would allow inspectors to focus on trouble spots. More
> Ben Venue trimming manufacturing, jobs at troubled plant. Story
> Zydus Cadila injects $160M into injectables. Report
> Coup de grâce for Boehringer Ingelheim Virginia plant. More
> Ukraine sentences drug counterfeiter to 4 years. Item
Biotech Research News
@EmilyMFierce: The latest at FierceBiotechResearch.com: Nerve cell death reversed in Parkinson's cells. Article | Follow @EmilyMFierce
> Industry-acade
> Diabetes progression slowed in mice. Story
> Inovio vaccine kills malaria, boosts immune response in animals. More
> Pluristem's stem cell therapy improves tendon injuries in rats. Item
> Seattle BioMed wins $16M NIH grant for TB research. Article